Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Toxoplasma Test Added to Benchtop Analyzer's Detection Portfolio

By LabMedica International staff writers
Posted on 16 Sep 2013
A major advance in the detection of infection by the parasite Toxoplasma gondii was marked by release of a molecular diagnostic kit for use in a sophisticated benchtop analyzer.

DiaSorin (Saluggia, Italy) has recently introduced a dedicated assay for T. More...
gondii for use on its Liaison Iam instrument, which is based on proprietary Q-LAMP isothermal amplification technology.

This technology offers all the benefits of isothermal LAMP (Loop Mediated Isothermal Amplification) but with the addition of real time, fluorescent, multiplexed amplification. In addition, Q-LAMP provides for single tube RNA amplification without the need for a reverse transcription step. With multiple recognition events per reaction, the DiaSorin Q-LAMP is highly specific and offers sensitivity on a par with real-time PCR. Detection of the amplified products is achieved with Q-Primers, which are labeled with a unique fluorophore that is quenched in the presence of the target sequence. The reduction of fluorescence is used to monitor the reaction and using a concept called time threshold (TT), together with known calibrators, can be used to quantify an unknown sample containing the target sequence.

All DiaSorin Q-LAMP assays are performed on a uniquely designed small footprint, bench top analyzer, the Liaison Iam analyzer. The analyzer is connected to an Iam Control Unit (ICU) via a USB interface. The ICU runs uniquely designed, simple to use software in which a graphical user interface guides the operator through a series of simple set up steps. From one to six instruments can be connected to a single ICU, allowing laboratories to start with a small number of tests and then add units as the workload or test portfolio grows.

“Iam Toxo rapidly confirms toxo infection,” said Paul Eros, global vice president molecular at DiaSorin. “The diagnostic sensitivity of the assay has been proven to be equivalent to PCR but delivers results produced in a fraction of the time that PCR requires. This assay is the latest addition to the unique and rapidly expanding DiaSorin Q-LAMP assay portfolio for our Liaison Iam molecular instrument, an easy-to-use benchtop device, which provides laboratories with a cost-effective, saleable, molecular diagnostic solution. This is a perfect solution for use in laboratory facilities of all sizes, including those that are located close to the patient.”

“DiaSorin Q-LAMP assays provide many advantages,” said Dr. Eros. “They are rapid, real-time, fluorescent, quantitative/qualitative assays designed to be used for multiplexed applications, enabling amplification and detection of multiple targets in a single reaction. Iam Toxo is a duplex fluorescent Q-LAMP assay employing primers designed to recognize a multicopy repeat region of the Toxoplasma gondii genome, common to all clinically-relevant subtypes.”

The Iam Toxo assay, when used with the Liaison Iam instrument, can be used for the detection of all clinically relevant subtypes of T. gondii in human plasma, CSF, and amniotic fluid.

Related Links:
DiaSorin



Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Urine Chemistry Control
Dropper Urine Chemistry Control
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.